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The	flaws	of	randomised	controlled	trials	and	the
reproducibility	crisis
Randomised	controlled	trials	(RCTs)	are	generally	viewed	as	the	foundational	experimental	method	of	the	social	and
medical	sciences.	Economists	depend	on	them,	for	certain	questions,	as	their	most	valued	method.	Yet	RCTs	are
not	flawless.	In	my	study,	“Why	all	randomised	controlled	trials	produce	biased	results”,	I	argue	that	RCTs	are	not
able	to	establish	precise	causal	effects	of	an	intervention.
Many	of	us	have	likely	used	some	medication,	own	some	technology,	or	support	some	public	policy	tested	in	a	trial.
To	be	able	to	assess	how	effective	they	may	be	prior	to	supporting	them	—	either	as	patients	or	consumers	or	voters
—	RCTs	are	often	conducted	by	splitting	up	a	sample	of	people	into	a	treatment	group	and	a	control	group.	Contrary
to	common	belief,	I	argue	that	some	degree	of	bias	inevitably	arises	in	any	trial.	This	is	because	some	share	of
recruited	people	refuse	to	participate	in	any	trial	(which	leads	to	sample	bias),	some	degree	of	partial	blinding	or
unblinding	of	the	various	trial	persons	generally	arises	in	any	trial	(which	leads	to	selection	bias),	and	participants
generally	take	treatment	for	different	lengths	of	time	and	different	dosages	in	any	trial	(which	leads	to	measurement
bias),	among	other	issues.
The	ten	most-cited	RCTs	worldwide,	which	I	assess	in	the	study,	suffer	from	such	general	issues.	But	they	also
suffer	from	other	methodological	issues	that	affect	their	estimated	results	as	well:	participants’	background
characteristics	(like	age,	health	status,	level	of	need	for	treatment,	etc.)	are	often	poorly	allocated	across	trial	groups,
participants	at	times	switch	between	trial	groups,	and	trials	often	neglect	alternative	factors	contributing	to	their	main
reported	outcome,	among	others.	Some	of	these	issues	cannot	be	avoided	in	trials—but	they	affect	the	robustness
and	validity	of	their	results	and	conclusions.
This	is	important	as	the	level	of	validity	of	a	trial’s	causal	claims	is	at	times	a	life-or-death	matter—for	example	in
public	health.	The	study	itself	is	about	the	RCT	method	and	not	any	individual	RCTs,	and	the	insights	outlined	are
useful	and	important	for	researchers	using	RCTs	in	economics,	psychology,	agriculture,	and	the	like	(though	the	ten
most-cited	RCTs	worldwide	that	are	assessed	happen	to	be	medical	trials).
Assumptions	and	biases	generally	increase	at	each	step	when	carrying	out	trials
That	is,	from	how	we	create	our	variables,	select	our	initial	sample,	and	randomise	participants	into	trial	groups,	to
how	we	analyse	the	data	for	participants	with	different	lengths	of	time	and	amounts	of	treatment,	and	how	we	try	and
ensure	everyone	involved	is	fully	blinded	before	the	trial	begins	and	throughout	its	entire	implementation—among
many	other	steps	before,	in	between,	and	after	these.
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I	thus	argue	that	the	reproducibility	crisis	is,	to	a	large	extent,	the	result	of	the	scientific	process	always	being	a
complex	human	process	that	involves	many	actors	(study	designers,	all	participants,	data	collectors,	implementing
practitioners,	study	statisticians,	etc.)	who	must	make	many	unique	decisions	at	many	different	steps	over	time	when
designing,	implementing,	and	analysing	any	given	study—and	some	degree	of	bias	unavoidably	arises	during	this
process.	Variation	between	study	outcomes	is	thus	the	norm,	and	one-to-one	replication	is	not	possible.
Researchers	should	thus	not	assume	that	the	RCT	method	inevitably	produces	valid	causal	results—in	fact,	that	all
trials	face	some	degree	of	bias	is	simply	the	trade-off	for	studies	to	actually	be	conducted	in	the	real	world.	A	number
of	things	inevitably	do	not	go	as	planned	or	designed	given	the	multiple	complex	processes	over	time	involved	in
carrying	out	trials.	Once	a	study	is	conducted	and	completed	some	biases	will	have	arisen	and	nothing	can	be	done
about	a	number	of	them.	The	study,	at	the	same	time,	aims	to	improve	how	RCTs	are	carried	out	by	outlining	how
researchers	can	reduce	some	of	the	biases.
Are	biased	results	in	trials	still	good	enough	to	inform	our	decisions	in	public	health	and	social	policy?
In	many	cases	they	are.	But	that	judgement	generally	depends	on	how	useful	the	results	are	in	practice	and	their
level	of	robustness	relative	to	other	studies	that	use	the	same	method	or,	at	times,	other	methods.	Yet	no	single
study	should	be	the	sole	and	authoritative	source	used	to	inform	policy	and	our	decisions.
Some	may	respond,	“are	RCTs	not	still	more	credible	than	other	methods	even	if	they	may	have	biases?”	For	most
questions	we	are	interested	in,	RCTs	cannot	be	more	credible	because	they	cannot	be	applied	—	e.g.	for	most
complex	phenomena	we	study,	such	as	effective	government	institutions,	long	life	expectancy,	democracy,
inequality,	education	systems,	psychological	states,	etc.	Other	methods	(such	as	observational	studies)	are	needed
for	many	questions	generally	not	amendable	to	randomisation	but	also	at	times	to	help	design	trials,	interpret	and
validate	their	results,	provide	further	insight	on	the	broader	conditions	under	which	treatments	may	work,	among
other	reasons	discussed	in	the	study.	Different	methods	are	thus	complements	(not	rivals)	in	improving
understanding.
Taken	together,	researchers,	practitioners,	and	policymakers	need	to	become	better	aware	of	the	broader	range	of
biases	facing	trials.	Journals	need	to	begin	to	require	researchers	to	outline	in	detail	the	assumptions,	biases,	and
limitations	in	their	studies.	If	researchers	do	not	report	this	crucial	information,	practitioners	and	citizens	will	have	to
just	rely	on	information	and	warning	labels	provided	by	policymakers,	biopharmaceutical	companies,	and	the	like
implementing	the	tested	policies	and	selling	the	tested	treatments.
♣♣♣
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